Abbisko Therapeutics Initiates Phase II Clinical Trial for Pimicotinib in Tendon Sheath Giant Cell Tumor
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the dosing of the first...
Drug
Astellas Pharma’s Zolbetuximab BLA Accepted by China’s CDE for Gastric Cancer Treatment
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that the Center for Drug Evaluation (CDE)...
GSK’s Jemperli Receives FDA Approval for First-Line Treatment of Advanced Endometrial Cancer
GSK plc (NYSE: GSK), a major UK pharmaceutical company, has announced that the US Food...
Viatris Inc. Secures FDA Nod for Generic Symbicort Equivalent, Breyna
US-based Viatris Inc., (NASDAQ: VTRS) has announced that the US Food and Drug Administration (FDA)...
RemeGen’s Novel Bispecific Antibody RC148 Receives Clinical Trial Approval
China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has announced that it has received clinical trial...
Jiangsu Hengrui’s Camrelizumab and Apatinib Combo Accepted for FDA Review for HCC Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that the US Food and Drug...
Jacobio Pharma’s Glecirasib Enters Breakthrough Therapy Review for Pancreatic Cancer Treatment
China-based Jacobio Pharma (HKG: 1167) has announced that its novel KRAS G12C inhibitor, glecirasib, has...
Jiangsu Aidea’s ACC008 Demonstrates Non-Inferior Efficacy to Genvoya in Phase III HIV Study
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced the summary report of a Phase...
Everest Medicines Completes Enrollment for Nefecon’s Phase III Extension Study in China
China-based Everest Medicines (HKG: 1952) has announced the completion of patient enrollment for the China...
Transcenta Holdings Gets CDE Approval for Phase II Study of TST002 for Bone Density
China-based biotech company Transcenta Holdings Ltd (HKG: 6628) has announced that it has received approval...
Zelgen Biopharmaceuticals’ ZG006 Earns NMPA Approval for Clinical Trials in Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a China-based biopharmaceutical company, has announced that it...
Shanghai Benemae’s Benaglutide Approved by NMPA for Adult Weight Management in China
The National Medical Products Administration (NMPA) has indicated on its website that benaglutide, developed by...
Nanjing Leads Biolabs’ LBL-034 Secures Clinical Trial Approvals from NMPA and FDA
Nanjing Leads Biolabs Co., Ltd, a China-based biopharmaceutical company, has announced receiving clinical trial approvals...
Huadong Medicine Receives NMPA Approval for Phase I Clinical Trial of DR10624 for Weight Management
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
Akeso Biopharma Initiates Phase Ia/Ib Study for TIGIT mAb AK127 in Solid Tumors Combination Therapy
China-based Akeso Biopharma (HKG: 9926) has announced the first patient enrollment in a Phase Ia/Ib...
Eli Lilly’s Tirzepatide Demonstrates Up to 26.6% Weight Loss in Phase III Obesity Studies
US pharmaceutical major Eli Lilly & Co., (NYSE: LLY) has released final results from two...
Sino Biopharmaceutical Receives NMPA Approval for Biosimilar Herceptin for HER2+ Cancers
Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received market approval from the...
Eli Lilly’s Donanemab Shows Significant Slowdown in Alzheimer’s Disease Progression in Phase III Study
US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has revealed the complete results of...
Jiangsu Simcere Pharmaceutical Receives NMPA Approval for Atopic Dermatitis Drug SIM0278
China’s Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that it has received clinical...